{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:17:45Z","timestamp":1794273465071,"version":"4.9.0"},"reference-count":120,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T00:00:00Z","timestamp":1686960000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T00:00:00Z","timestamp":1686960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"ICO Cancer center","award":["Internal support"],"award-info":[{"award-number":["Internal support"]}]},{"name":"R\u00e9gion des Pays de la loire","award":["Th\u00e8se Tandem Program"],"award-info":[{"award-number":["Th\u00e8se Tandem Program"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>This article gives a brief overview of the most recent developments in osteosarcoma treatment, including targeting of signaling pathways, immune checkpoint inhibitors, drug delivery strategies as single or combined approaches, and the identification of new therapeutic targets to face this highly heterogeneous disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Osteosarcoma is one of the most common primary malignant bone tumors in children and young adults, with a high risk of bone and lung metastases and a 5-year survival rate around 70% in the absence of metastases and 30% if metastases are detected at the time of diagnosis. Despite the novel advances in neoadjuvant chemotherapy, the effective treatment for osteosarcoma has not improved in the last 4 decades. The emergence of immunotherapy has transformed the paradigm of treatment, focusing therapeutic strategies on the potential of immune checkpoint inhibitors. However, the most recent clinical trials show a slight improvement over the conventional polychemotherapy scheme.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>The tumor microenvironment plays a crucial role in the pathogenesis of osteosarcoma by controlling the tumor growth, the metastatic process and the drug resistance and paved the way of new therapeutic options that must be validated by accurate pre-clinical studies and clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11914-023-00803-9","type":"journal-article","created":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T02:02:10Z","timestamp":1686967330000},"page":"330-343","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":124,"title":["Advances in Osteosarcoma"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0060-7502","authenticated-orcid":false,"given":"Isidora","family":"Panez-Toro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2978-1192","authenticated-orcid":false,"given":"Javier","family":"Mu\u00f1oz-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge W.","family":"Vargas-Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3924-7372","authenticated-orcid":false,"given":"Axelle","family":"Renodon-Corni\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5585-8261","authenticated-orcid":false,"given":"Marie-Fran\u00e7oise","family":"Heymann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6274-6981","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"L\u00e9zot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7777-0669","authenticated-orcid":false,"given":"Dominique","family":"Heymann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,17]]},"reference":[{"key":"803_CR1","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.3390\/ijms24031946","volume":"24","author":"M Rossi","year":"2023","unstructured":"Rossi M, Del Fattore A. Molecular and translational research on bone tumors. Int J Mol Sci. 2023;24:1946.","journal-title":"Int J Mol Sci."},{"key":"803_CR2","first-page":"92","volume":"9","author":"A Franchi","year":"2012","unstructured":"Franchi A. Epidemiology and classification of bone tumors. Clin Cases Miner Bone Metab Off J Ital Soc Osteoporos Miner Metab Skelet Dis. 2012;9:92\u20135.","journal-title":"Clin Cases Miner Bone Metab Off J Ital Soc Osteoporos Miner Metab Skelet Dis"},{"key":"803_CR3","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00280-017-3436-0","volume":"80","author":"A Redondo","year":"2017","unstructured":"Redondo A, Bagu\u00e9 S, Bernabeu D, et al. Malignant bone tumors (other than Ewing\u2019s): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS). Cancer Chemother Pharmacol. 2017;80:1113\u201331.","journal-title":"Cancer Chemother Pharmacol"},{"key":"803_CR4","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1007\/s00223-017-0372-2","volume":"102","author":"HK Brown","year":"2018","unstructured":"Brown HK, Schiavone K, Gouin F, Heymann M-F, Heymann D. Biology of bone sarcomas and new therapeutic developments. Calcif Tissue Int. 2018;102:174\u201395.","journal-title":"Calcif Tissue Int"},{"key":"803_CR5","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.mayocp.2012.01.015","volume":"87","author":"CAS Arndt","year":"2012","unstructured":"Arndt CAS, Rose PS, Folpe AL, Laack NN. Common musculoskeletal tumors of childhood and adolescence. Mayo Clin Proc. 2012;87:475\u201387.","journal-title":"Mayo Clin Proc"},{"key":"803_CR6","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1186\/s13063-022-06590-5","volume":"23","author":"K Mann","year":"2022","unstructured":"Mann K, Waters AR, Park ER, et al. HIAYA CHAT study protocol: a randomized controlled trial of a health insurance education intervention for newly diagnosed adolescent and young adult cancer patients. Trials. 2022;23:682.","journal-title":"Trials"},{"key":"803_CR7","doi-asserted-by":"publisher","first-page":"153303382211173","DOI":"10.1177\/15330338221117386","volume":"21","author":"Z Dong","year":"2022","unstructured":"Dong Z, Liao Z, He Y, et al. Advances in the biological functions and mechanisms of miRNAs in the development of osteosarcoma. Technol Cancer Res Treat. 2022;21:153303382211173.","journal-title":"Technol Cancer Res Treat"},{"key":"803_CR8","doi-asserted-by":"publisher","first-page":"698282","DOI":"10.3389\/fcell.2022.698282","volume":"10","author":"Z Peng","year":"2022","unstructured":"Peng Z, Li M, Wang Y, et al. Self-assembling imageable silk hydrogels for the focal treatment of osteosarcoma. Front Cell Dev Biol. 2022;10:698282.","journal-title":"Front Cell Dev Biol"},{"key":"803_CR9","doi-asserted-by":"publisher","first-page":"843345","DOI":"10.3389\/fonc.2022.843345","volume":"12","author":"D Xie","year":"2022","unstructured":"Xie D, Wang Z, Li J, Guo D, Lu A, Liang C. Targeted delivery of chemotherapeutic agents for osteosarcoma treatment. Front Oncol. 2022;12:843345.","journal-title":"Front Oncol"},{"key":"803_CR10","doi-asserted-by":"publisher","first-page":"115523","DOI":"10.1016\/j.bone.2020.115523","volume":"139","author":"M-F Heymann","year":"2020","unstructured":"Heymann M-F, Lezot F, Heymann D. Bisphosphonates in common pediatric and adult bone sarcomas. Bone. 2020;139:115523.","journal-title":"Bone"},{"key":"803_CR11","doi-asserted-by":"publisher","first-page":"8940","DOI":"10.1038\/ncomms9940","volume":"6","author":"M Kovac","year":"2015","unstructured":"Kovac M, Blattmann C, Ribi S, et al. Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency. Nat Commun. 2015;6:8940.","journal-title":"Nat Commun"},{"key":"803_CR12","doi-asserted-by":"publisher","first-page":"976","DOI":"10.3390\/cells9040976","volume":"9","author":"I Corre","year":"2020","unstructured":"Corre I, Verrecchia F, Crenn V, Redini F, Trichet V. The osteosarcoma microenvironment: a complex but targetable ecosystem. Cells. 2020;9:976.","journal-title":"Cells"},{"key":"803_CR13","doi-asserted-by":"publisher","first-page":"e11131","DOI":"10.15252\/emmm.201911131","volume":"12","author":"TG Gr\u00fcnewald","year":"2020","unstructured":"Gr\u00fcnewald TG, Alonso M, Avnet S, et al. Sarcoma treatment in the era of molecular medicine. EMBO Mol Med. 2020;12:e11131.","journal-title":"EMBO Mol Med"},{"key":"803_CR14","doi-asserted-by":"publisher","first-page":"103711","DOI":"10.1016\/j.cellimm.2017.10.011","volume":"343","author":"M-F Heymann","year":"2019","unstructured":"Heymann M-F, L\u00e9zot F, Heymann D. The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma. Cell Immunol. 2019;343:103711.","journal-title":"Cell Immunol"},{"key":"803_CR15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.canlet.2016.11.019","volume":"386","author":"HK Brown","year":"2017","unstructured":"Brown HK, Tellez-Gabriel M, Heymann D. Cancer stem cells in osteosarcoma. Cancer Lett. 2017;386:189\u201395.","journal-title":"Cancer Lett"},{"key":"803_CR16","doi-asserted-by":"publisher","first-page":"732862","DOI":"10.3389\/fonc.2022.732862","volume":"12","author":"J Guo","year":"2022","unstructured":"Guo J, Tang H, Huang P, Guo J, Shi Y, Yuan C, Liang T, Tang K. Single-cell profiling of tumor microenvironment heterogeneity in osteosarcoma identifies a highly invasive subcluster for predicting prognosis. Front Oncol. 2022;12:732862.","journal-title":"Front Oncol"},{"key":"803_CR17","doi-asserted-by":"publisher","first-page":"6322","DOI":"10.1038\/s41467-020-20059-6","volume":"11","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Yang D, Yang Q, et al. Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma. Nat Commun. 2020;11:6322. Interesting manuscript deciphering the immune suppressive landscape in osteosarcoma by single cell RNA sequencing.","journal-title":"Nat Commun"},{"key":"803_CR18","doi-asserted-by":"publisher","first-page":"1042625","DOI":"10.3389\/fbioe.2022.1042625","volume":"10","author":"H Tian","year":"2022","unstructured":"Tian H, Wu R, Feng N, Zhang J, Zuo J. Recent advances in hydrogels-based osteosarcoma therapy. Front Bioeng Biotechnol. 2022;10:1042625.","journal-title":"Front Bioeng Biotechnol"},{"key":"803_CR19","first-page":"184","volume":"5","author":"C Jubelin","year":"2022","unstructured":"Jubelin C, Mu\u00f1oz-Garcia J, Cochonneau D, Moranton E, Heymann M-F, Heymann D. Biological evidence of cancer stem-like cells and recurrent disease in osteosarcoma. Cancer Drug Resist. 2022;5:184\u201398.","journal-title":"Cancer Drug Resist"},{"key":"803_CR20","doi-asserted-by":"publisher","first-page":"897641","DOI":"10.3389\/fbioe.2022.897641","volume":"10","author":"Y Xu","year":"2022","unstructured":"Xu Y, Qi J, Sun W, Zhong W, Wu H. Therapeutic effects of zoledronic acid-loaded hyaluronic acid\/polyethylene glycol\/nano-hydroxyapatite nanoparticles on osteosarcoma. Front Bioeng Biotechnol. 2022;10:897641.","journal-title":"Front Bioeng Biotechnol"},{"key":"803_CR21","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.cytogfr.2004.06.004","volume":"15","author":"S Theoleyre","year":"2004","unstructured":"Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann D. The molecular triad OPG\/RANK\/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev. 2004;15:457\u201375.","journal-title":"Cytokine Growth Factor Rev"},{"key":"803_CR22","doi-asserted-by":"publisher","first-page":"6865","DOI":"10.3390\/ijms22136865","volume":"22","author":"KS N\u00f8rregaard","year":"2021","unstructured":"N\u00f8rregaard KS, J\u00fcrgensen HJ, G\u00e5rdsvoll H, Engelholm LH, Behrendt N, S\u00f8e K. Osteosarcoma and metastasis associated bone degradation\u2014a tale of osteoclast and malignant cell cooperativity. Int J Mol Sci. 2021;22:6865.","journal-title":"Int J Mol Sci"},{"key":"803_CR23","doi-asserted-by":"publisher","first-page":"7063","DOI":"10.1158\/0008-5472.CAN-09-4291","volume":"70","author":"L Endo-Munoz","year":"2010","unstructured":"Endo-Munoz L, Cumming A, Rickwood D, et al. Loss of osteoclasts contributes to development of osteosarcoma pulmonary metastases. Cancer Res. 2010;70:7063\u201372.","journal-title":"Cancer Res"},{"key":"803_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41572-022-00409-y","volume":"8","author":"HC Beird","year":"2022","unstructured":"Beird HC, Bielack SS, Flanagan AM, Gill J, Heymann D, Janeway KA, Livingston JA, Roberts RD, Strauss SJ, Gorlick R. Osteosarcoma. Nat Rev Dis Primer. 2022;8:77.","journal-title":"Nat Rev Dis Primer"},{"key":"803_CR25","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/path.2140","volume":"211","author":"K Mori","year":"2007","unstructured":"Mori K, Le Goff B, Berreur M, et al. Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B. J Pathol. 2007;211:555\u201362.","journal-title":"J Pathol"},{"key":"803_CR26","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jbo.2015.06.002","volume":"4","author":"D Branstetter","year":"2015","unstructured":"Branstetter D, Rohrbach K, Huang L-Y, Soriano R, Tometsko M, Blake M, Jacob AP, Dougall WC. RANK and RANK ligand expression in primary human osteosarcoma. J Bone Oncol. 2015;4:59\u201368.","journal-title":"J Bone Oncol"},{"key":"803_CR27","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.3892\/etm.2017.4360","volume":"13","author":"J Zhu","year":"2017","unstructured":"Zhu J, Liu Y, Zhu Y, Zeng M, Xie J, Lei P, Li K, Hu Y. Role of RANK and Akt1 activation in human osteosarcoma progression: a clinicopathological study. Exp Ther Med. 2017;13:2862\u20136.","journal-title":"Exp Ther Med"},{"key":"803_CR28","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.3892\/ol.2015.3489","volume":"10","author":"K Trieb","year":"2015","unstructured":"Trieb K, Windhager R. Receptor activator of nuclear factor \u03baB expression is a prognostic factor in human osteosarcoma. Oncol Lett. 2015;10:1813\u20135.","journal-title":"Oncol Lett"},{"key":"803_CR29","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1002\/jbmr.455","volume":"26","author":"J Rousseau","year":"2011","unstructured":"Rousseau J, Escriou V, Lamoureux F, et al. Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models. J Bone Miner Res. 2011;26:2452\u201362.","journal-title":"J Bone Miner Res"},{"key":"803_CR30","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1158\/0008-5472.CAN-08-2648","volume":"69","author":"F Lamoureux","year":"2009","unstructured":"Lamoureux F, Picarda G, Garrigue-Antar L, Baud\u2019huin M, Trichet V, Vidal A, Miot-Noirault E, Pitard B, Heymann D, R\u00e9dini F. Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma. Cancer Res. 2009;69:526\u201336.","journal-title":"Cancer Res"},{"key":"803_CR31","doi-asserted-by":"publisher","first-page":"7308","DOI":"10.1158\/0008-5472.CAN-06-4130","volume":"67","author":"F Lamoureux","year":"2007","unstructured":"Lamoureux F, Richard P, Wittrant Y, et al. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Res. 2007;67:7308\u201318.","journal-title":"Cancer Res"},{"key":"803_CR32","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3390\/cancers10110398","volume":"10","author":"B Navet","year":"2018","unstructured":"Navet B, Ando K, Vargas-Franco J, et al. The intrinsic and extrinsic implications of rankl\/rank signaling in osteosarcoma: from tumor initiation to lung metastases. Cancers. 2018;10:398.","journal-title":"Cancers"},{"key":"803_CR33","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.18632\/oncotarget.27669","volume":"11","author":"F Punzo","year":"2020","unstructured":"Punzo F, Tortora C, Argenziano M, Pinto DD, Pota E, Martino MD, Paola AD, Rossi F. Can denosumab be used in combination with doxorubicin in osteosarcoma? Oncotarget. 2020;11:2763\u201373.","journal-title":"Oncotarget"},{"key":"803_CR34","doi-asserted-by":"publisher","first-page":"e13088","DOI":"10.14814\/phy2.13088","volume":"5","author":"MG Johnson","year":"2017","unstructured":"Johnson MG, Konicke K, Kristianto J, Gustavson A, Garbo R, Wang X, Yuan B, Blank RD. Endothelin signaling regulates mineralization and posttranscriptionally regulates SOST in TMOb cells via miR 126-3p. Physiol Rep. 2017;5:e13088.","journal-title":"Physiol Rep"},{"key":"803_CR35","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.3390\/cancers14071765","volume":"14","author":"J Mu\u00f1oz-Garcia","year":"2022","unstructured":"Mu\u00f1oz-Garcia J, Vargas-Franco JW, Royer BB-L, Cochonneau D, Amiaud J, Heymann M-F, Heymann D, L\u00e9zot F. Inhibiting endothelin receptors with macitentan strengthens the bone protective action of RANKL inhibition and reduces metastatic dissemination in osteosarcoma. Cancers. 2022;14:1765.","journal-title":"Cancers"},{"key":"803_CR36","doi-asserted-by":"publisher","first-page":"36780","DOI":"10.18632\/oncotarget.26377","volume":"9","author":"F Fang","year":"2018","unstructured":"Fang F, VanCleave A, Helmuth R, Torres H, Rickel K, Wollenzien H, Sun H, Zeng E, Zhao J, Tao J. Targeting the Wnt\/\u03b2-catenin pathway in human osteosarcoma cells. Oncotarget. 2018;9:36780\u201392.","journal-title":"Oncotarget"},{"key":"803_CR37","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/bph.15713","volume":"179","author":"Z Shoaib","year":"2022","unstructured":"Shoaib Z, Fan TM, Irudayaraj JMK. Osteosarcoma mechanobiology and therapeutic targets. Br J Pharmacol. 2022;179:201\u201317.","journal-title":"Br J Pharmacol"},{"key":"803_CR38","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3390\/ph14050421","volume":"14","author":"G Danieau","year":"2021","unstructured":"Danieau G, Morice S, Renault S, et al. ICG-001, an inhibitor of the \u03b2-catenin and cAMP response element-binding protein dependent gene transcription, decreases proliferation but enhances migration of osteosarcoma cells. Pharmaceuticals. 2021;14:421.","journal-title":"Pharmaceuticals"},{"key":"803_CR39","doi-asserted-by":"publisher","first-page":"104069","DOI":"10.1016\/j.ebiom.2022.104069","volume":"80","author":"K Kimura","year":"2022","unstructured":"Kimura K, Kanto T, Shimoda S, et al. Safety, tolerability, and anti-fibrotic efficacy of the CBP\/\u03b2-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: an investigator-initiated, open-label, non-randomised, multicentre, phase 1\/2a study. eBioMedicine. 2022;80:104069.","journal-title":"eBioMedicine"},{"key":"803_CR40","doi-asserted-by":"publisher","first-page":"573962","DOI":"10.3389\/fbioe.2020.573962","volume":"8","author":"Y Sun","year":"2020","unstructured":"Sun Y, Li K, Li C, Zhang Y, Zhao D. Thermogel delivers oxaliplatin and alendronate in situ for synergistic osteosarcoma therapy. Front Bioeng Biotechnol. 2020;8:573962.","journal-title":"Front Bioeng Biotechnol"},{"key":"803_CR41","doi-asserted-by":"publisher","first-page":"13280","DOI":"10.1080\/21655979.2022.2080363","volume":"13","author":"X Liu","year":"2022","unstructured":"Liu X, Geng Z, Ding X, Lou Y, Zhang X. Convallatoxin suppresses osteosarcoma cell proliferation, migration, invasion, and enhances osteogenic differentiation by downregulating parathyroid hormone receptor 1 (PTHR1) expression and inactivating Wnt\/\u03b2-catenin pathway. Bioengineered. 2022;13:13280\u201392.","journal-title":"Bioengineered"},{"key":"803_CR42","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/hep.29405","volume":"67","author":"J Zhang","year":"2018","unstructured":"Zhang J, Li Z, Liu L, et al. Long noncoding RNA TSLNC8 is a tumor suppressor that inactivates the interleukin-6\/STAT3 signaling pathway. Hepatology. 2018;67:171\u201387.","journal-title":"Hepatology"},{"key":"803_CR43","doi-asserted-by":"crossref","unstructured":"Qu Z, Li S. Long noncoding RNA LINC01278 favors the progression of osteosarcoma via modulating miR133a-3p\/PTHR1 signaling. J Cell Physiol. 2020;jcp.29582","DOI":"10.1002\/jcp.29582"},{"key":"803_CR44","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1002\/vms3.614","volume":"7","author":"M Morimoto","year":"2021","unstructured":"Morimoto M, Tatsumi K, Yuui K, Terazawa I, Kudo R, Kasuda S. Convallatoxin, the primary cardiac glycoside in lily of the valley ( Convallaria majalis ), induces tissue factor expression in endothelial cells. Vet Med Sci. 2021;7:2440\u20134.","journal-title":"Vet Med Sci"},{"key":"803_CR45","doi-asserted-by":"publisher","first-page":"153172","DOI":"10.1016\/j.phymed.2020.153172","volume":"68","author":"ZH Zhang","year":"2020","unstructured":"Zhang ZH, Li MY, Wang Z, et al. Convallatoxin promotes apoptosis and inhibits proliferation and angiogenesis through crosstalk between JAK2\/STAT3 (T705) and mTOR\/STAT3 (S727) signaling pathways in colorectal cancer. Phytomedicine. 2020;68:153172.","journal-title":"Phytomedicine"},{"key":"803_CR46","doi-asserted-by":"publisher","first-page":"1031779","DOI":"10.3389\/fonc.2022.1031779","volume":"12","author":"X Liu","year":"2022","unstructured":"Liu X, Du S, Wang S, Ye K. Ferroptosis in osteosarcoma: a promising future. Front Oncol. 2022;12:1031779.","journal-title":"Front Oncol"},{"key":"803_CR47","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40880-018-0288-x","volume":"38","author":"P Koppula","year":"2018","unstructured":"Koppula P, Zhang Y, Zhuang L, Gan B. Amino acid transporter SLC7A11\/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer. Cancer Commun. 2018;38:12.","journal-title":"Cancer Commun"},{"key":"803_CR48","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/s41556-020-0496-x","volume":"22","author":"X Liu","year":"2020","unstructured":"Liu X, Olszewski K, Zhang Y, et al. Cystine transporter regulation of pentose phosphate pathway dependency and disulfide stress exposes a targetable metabolic vulnerability in cancer. Nat Cell Biol. 2020;22:476\u201386.","journal-title":"Nat Cell Biol"},{"key":"803_CR49","doi-asserted-by":"publisher","unstructured":"Li L, Zhang Y, Gao Y, Hu Y, Wang R, Wang S, Li Y, He Y, Yuan C. LncSNHG14 promotes nutlin3a resistance by inhibiting ferroptosis via the miR-206 \/SLC7A11 axis in osteosarcoma cells. Cancer Gene Ther. 2023; https:\/\/doi.org\/10.1038\/s41417-022-00581-z.","DOI":"10.1038\/s41417-022-00581-z"},{"key":"803_CR50","doi-asserted-by":"publisher","first-page":"mfac027","DOI":"10.1093\/mtomcs\/mfac027","volume":"14","author":"J Liu","year":"2022","unstructured":"Liu J, Lou C, Zhen C, Wang Y, Shang P, Lv H. Iron plays a role in sulfasalazine-induced ferroptosis with autophagic flux blockage in K7M2 osteosarcoma cells. Metallomics. 2022;14:mfac027.","journal-title":"Metallomics"},{"key":"803_CR51","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.bbrc.2021.06.036","volume":"567","author":"Y Shi","year":"2021","unstructured":"Shi Y, Gong M, Deng Z, Liu H, Chang Y, Yang Z, Cai L. Tirapazamine suppress osteosarcoma cells in part through SLC7A11 mediated ferroptosis. Biochem Biophys Res Commun. 2021;567:118\u201324.","journal-title":"Biochem Biophys Res Commun"},{"key":"803_CR52","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1080\/10715762.2021.2024816","volume":"55","author":"Z Xu","year":"2021","unstructured":"Xu Z, Chen L, Wang C, Zhang L, Xu W. MicroRNA-1287-5p promotes ferroptosis of osteosarcoma cells through inhibiting GPX4. Free Radic Res. 2021;55:1119\u201329.","journal-title":"Free Radic Res"},{"key":"803_CR53","doi-asserted-by":"publisher","first-page":"100380","DOI":"10.1016\/j.jbo.2021.100380","volume":"30","author":"J Zhao","year":"2021","unstructured":"Zhao J, Zhao Y, Ma X, Zhang B, Feng H. Targeting ferroptosis in osteosarcoma. J Bone Oncol. 2021;30:100380.","journal-title":"J Bone Oncol"},{"key":"803_CR54","doi-asserted-by":"publisher","first-page":"871076","DOI":"10.3389\/fimmu.2022.871076","volume":"13","author":"L Yu","year":"2022","unstructured":"Yu L, Zhang J, Li Y. Effects of microenvironment in osteosarcoma on chemoresistance and the promise of immunotherapy as an osteosarcoma therapeutic modality. Front Immunol. 2022;13:871076.","journal-title":"Front Immunol"},{"key":"803_CR55","doi-asserted-by":"publisher","first-page":"215887","DOI":"10.1016\/j.canlet.2022.215887","volume":"547","author":"Y Wen","year":"2022","unstructured":"Wen Y, Tang F, Tu C, Hornicek F, Duan Z, Min L. Immune checkpoints in osteosarcoma: recent advances and therapeutic potential. Cancer Lett. 2022;547:215887.","journal-title":"Cancer Lett"},{"key":"803_CR56","doi-asserted-by":"publisher","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-11-1595","volume":"17","author":"EJ Lipson","year":"2011","unstructured":"Lipson EJ, Drake CG. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res. 2011;17:6958\u201362.","journal-title":"Clin Cancer Res"},{"key":"803_CR57","doi-asserted-by":"publisher","first-page":"6726","DOI":"10.1038\/s41467-021-26974-6","volume":"12","author":"D Phillips","year":"2021","unstructured":"Phillips D, Matusiak M, Gutierrez BR, et al. Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma. Nat Commun. 2021;12:6726.","journal-title":"Nat Commun"},{"key":"803_CR58","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s00280-022-04414-6","volume":"89","author":"E Felip","year":"2022","unstructured":"Felip E, Moreno V, Morgensztern D, et al. First-in-human, open-label, phase 1\/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers. Cancer Chemother Pharmacol. 2022;89:499\u2013514.","journal-title":"Cancer Chemother Pharmacol"},{"key":"803_CR59","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13045-020-01027-5","volume":"14","author":"M Yi","year":"2021","unstructured":"Yi M, Niu M, Xu L, Luo S, Wu K. Regulation of PD-L1 expression in the tumor microenvironment. J Hematol OncolJ Hematol Oncol. 2021;14:10.","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"803_CR60","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12885-019-6499-y","volume":"20","author":"K Yoshida","year":"2020","unstructured":"Yoshida K, Okamoto M, Sasaki J, et al. Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells. BMC Cancer. 2020;20:25.","journal-title":"BMC Cancer"},{"key":"803_CR61","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1002\/cam4.1518","volume":"7","author":"P Dhupkar","year":"2018","unstructured":"Dhupkar P, Gordon N, Stewart J, Kleinerman ES. Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases. Cancer Med. 2018;7:2654\u201364.","journal-title":"Cancer Med"},{"key":"803_CR62","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S1470-2045(20)30023-1","volume":"21","author":"KL Davis","year":"2020","unstructured":"Davis KL, Fox E, Merchant MS, et al. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1\u20132 trial. Lancet Oncol. 2020;21:541\u201350.","journal-title":"Lancet Oncol"},{"key":"803_CR63","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","volume":"18","author":"HA Tawbi","year":"2017","unstructured":"Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;18:1493\u2013501.","journal-title":"Lancet Oncol"},{"key":"803_CR64","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1007\/s00262-021-02876-w","volume":"70","author":"K Boye","year":"2021","unstructured":"Boye K, Longhi A, Guren T, et al. Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial. Cancer Immunol Immunother. 2021;70:2617\u201324.","journal-title":"Cancer Immunol Immunother"},{"key":"803_CR65","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ejca.2019.07.018","volume":"119","author":"A Le Cesne","year":"2019","unstructured":"Le Cesne A, Marec-Berard P, Blay J-Y, et al. Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study. Eur J Cancer. 2019;119:151\u20137.","journal-title":"Eur J Cancer"},{"key":"803_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaoncol.2020.3689","volume":"6","author":"SM Pollack","year":"2020","unstructured":"Pollack SM, Redman MW, Baker KK, et al. Assessment of doxorubicin and pembrolizumab in patients with advanced anthracycline-naive sarcoma. JAMA Oncol. 2020;6:1\u20135.","journal-title":"JAMA Oncol"},{"key":"803_CR67","doi-asserted-by":"publisher","first-page":"e001458","DOI":"10.1136\/jitc-2020-001458","volume":"9","author":"AM Starzer","year":"2021","unstructured":"Starzer AM, Berghoff AS, Hamacher R, et al. Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients. J Immunother Cancer. 2021;9:e001458.","journal-title":"J Immunother Cancer"},{"key":"803_CR68","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1158\/1078-0432.CCR-15-0491","volume":"22","author":"MS Merchant","year":"2016","unstructured":"Merchant MS, Wright M, Baird K, et al. Phase I clinical trial of ipilimumab in pediatric patients with advanced solid tumors. Clin Cancer Res. 2016;22:1364\u201370.","journal-title":"Clin Cancer Res"},{"key":"803_CR69","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1080\/17843286.2019.1683129","volume":"76","author":"L Nuytemans","year":"2021","unstructured":"Nuytemans L, Sys G, Creytens D, Lapeire L. NGS-analysis to the rescue: dual checkpoint inhibition in metastatic osteosarcoma \u2013 a case report and review of the literature. Acta Clin Belg. 2021;76:162\u20137.","journal-title":"Acta Clin Belg"},{"key":"803_CR70","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/S1470-2045(22)00392-8","volume":"23","author":"N Somaiah","year":"2022","unstructured":"Somaiah N, Conley AP, Parra ER, et al. Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial. Lancet Oncol. 2022;23:1156\u201366.","journal-title":"Lancet Oncol"},{"key":"803_CR71","doi-asserted-by":"publisher","first-page":"107933","DOI":"10.1016\/j.intimp.2021.107933","volume":"99","author":"L Zhao","year":"2021","unstructured":"Zhao L, Cheng S, Fan L, Zhang B, Xu S. TIM-3: an update on immunotherapy. Int Immunopharmacol. 2021;99:107933.","journal-title":"Int Immunopharmacol"},{"key":"803_CR72","doi-asserted-by":"publisher","first-page":"e001772","DOI":"10.1136\/jitc-2020-001772","volume":"9","author":"JA Ligon","year":"2021","unstructured":"Ligon JA, Choi W, Cojocaru G, et al. Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes. J Immunother Cancer. 2021;9:e001772.","journal-title":"J Immunother Cancer"},{"key":"803_CR73","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1111\/bph.14999","volume":"178","author":"M-F Heymann","year":"2021","unstructured":"Heymann M-F, Schiavone K, Heymann D. Bone sarcomas in the immunotherapy era. Br J Pharmacol. 2021;178:1955\u201372.","journal-title":"Br J Pharmacol"},{"key":"803_CR74","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1038\/s41467-020-14646-w","volume":"11","author":"C-C Wu","year":"2020","unstructured":"Wu C-C, Beird HC, Andrew Livingston J, et al. Immuno-genomic landscape of osteosarcoma. Nat Commun. 2020;11:1008. Interesting manuscript identifying potential immunotherapeutic targets in osteosarcoma.","journal-title":"Nat Commun"},{"key":"803_CR75","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1007\/s00018-015-1918-y","volume":"72","author":"A Alfranca","year":"2015","unstructured":"Alfranca A, Martinez-Cruzado L, Tornin J, Abarrategi A, Amaral T, de Alava E, Menendez P, Garcia-Castro J, Rodriguez R. Bone microenvironment signals in osteosarcoma development. Cell Mol Life Sci. 2015;72:3097\u2013113.","journal-title":"Cell Mol Life Sci"},{"key":"803_CR76","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.canlet.2017.07.024","volume":"405","author":"M Cortini","year":"2017","unstructured":"Cortini M, Avnet S, Baldini N. Mesenchymal stroma: role in osteosarcoma progression. Cancer Lett. 2017;405:90\u20139.","journal-title":"Cancer Lett"},{"key":"803_CR77","doi-asserted-by":"publisher","first-page":"100372","DOI":"10.1016\/j.jbo.2021.100372","volume":"29","author":"X Chang","year":"2021","unstructured":"Chang X, Ma Z, Zhu G, Lu Y, Yang J. New perspective into mesenchymal stem cells: Molecular mechanisms regulating osteosarcoma. J Bone Oncol. 2021;29:100372.","journal-title":"J Bone Oncol"},{"key":"803_CR78","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1126\/science.aay9189","volume":"368","author":"D Nejman","year":"2020","unstructured":"Nejman D, Livyatan I, Fuks G, et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science. 2020;368:973\u201380. Major contribution describing the presence of bacteria in tumor tissues and showing the diversity of the tumor microbiome.","journal-title":"Science"},{"key":"803_CR79","doi-asserted-by":"publisher","first-page":"100451","DOI":"10.1016\/j.jbo.2022.100451","volume":"36","author":"CJF Heymann","year":"2022","unstructured":"Heymann CJF, Bobin-Dubigeon C, Mu\u00f1oz-Garcia J, Cochonneau D, Ollivier E, Heymann M-F, Heymann D. Lipopolysaccharide-binding protein expression is associated to the metastatic status of osteosarcoma patients. J Bone Oncol. 2022;36:100451.","journal-title":"J Bone Oncol"},{"key":"803_CR80","doi-asserted-by":"publisher","first-page":"e10999","DOI":"10.1371\/journal.pone.0010999","volume":"5","author":"P Perrot","year":"2010","unstructured":"Perrot P, Rousseau J, Bouffaut A-L, et al. Safety concern between autologous fat graft, mesenchymal stem cell and osteosarcoma recurrence. PLoS One. 2010;5:e10999.","journal-title":"PLoS One"},{"key":"803_CR81","doi-asserted-by":"publisher","first-page":"100231","DOI":"10.1016\/j.jbo.2019.100231","volume":"16","author":"A Stamatopoulos","year":"2019","unstructured":"Stamatopoulos A, Stamatopoulos T, Gamie Z, Kenanidis E, Ribeiro RDC, Rankin KS, Gerrand C, Dalgarno K, Tsiridis E. Mesenchymal stromal cells for bone sarcoma treatment: roadmap to clinical practice. J Bone Oncol. 2019;16:100231.","journal-title":"J Bone Oncol"},{"key":"803_CR82","doi-asserted-by":"publisher","first-page":"3721","DOI":"10.1158\/1078-0432.CCR-16-2726","volume":"23","author":"SR Baglio","year":"2017","unstructured":"Baglio SR, Lagerweij T, P\u00e9rez-Lanz\u00f3n M, et al. Blocking tumor-educated MSC paracrine activity halts osteosarcoma progression. Clin Cancer Res. 2017;23:3721\u201333.","journal-title":"Clin Cancer Res"},{"key":"803_CR83","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.canlet.2012.06.006","volume":"325","author":"B Tu","year":"2012","unstructured":"Tu B, Du L, Fan Q-M, Tang Z, Tang T-T. STAT3 activation by IL-6 from mesenchymal stem cells promotes the proliferation and metastasis of osteosarcoma. Cancer Lett. 2012;325:80\u20138.","journal-title":"Cancer Lett"},{"key":"803_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2020.12.024","volume":"500","author":"C Chen","year":"2021","unstructured":"Chen C, Xie L, Ren T, Huang Y, Xu J, Guo W. Immunotherapy for osteosarcoma: fundamental mechanism, rationale, and recent breakthroughs. Cancer Lett. 2021;500:1\u201310.","journal-title":"Cancer Lett"},{"key":"803_CR85","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.3389\/fimmu.2019.01408","volume":"10","author":"M-B Madel","year":"2019","unstructured":"Madel M-B, Ib\u00e1\u00f1ez L, Wakkach A, de Vries TJ, Teti A, Apparailly F, Blin-Wakkach C. Immune function and diversity of osteoclasts in normal and pathological conditions. Front Immunol. 2019;10:1408.","journal-title":"Front Immunol"},{"key":"803_CR86","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1158\/2326-6066.CIR-16-0259","volume":"5","author":"Q Zhou","year":"2017","unstructured":"Zhou Q, Xian M, Xiang S, et al. All-trans retinoic acid prevents osteosarcoma metastasis by inhibiting M2 polarization of tumor-associated macrophages. Cancer Immunol Res. 2017;5:547\u201359.","journal-title":"Cancer Immunol Res"},{"key":"803_CR87","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.3390\/cancers12113457","volume":"12","author":"A Mazumdar","year":"2020","unstructured":"Mazumdar A, Urdinez J, Boro A, et al. Exploring the role of osteosarcoma-derived extracellular vesicles in pre-metastatic niche formation and metastasis in the 143-B xenograft mouse osteosarcoma model. Cancers. 2020;12:3457.","journal-title":"Cancers"},{"key":"803_CR88","doi-asserted-by":"publisher","first-page":"e99791","DOI":"10.1172\/jci.insight.99791","volume":"3","author":"AC Gross","year":"2018","unstructured":"Gross AC, Cam H, Phelps DA, et al. IL-6 and CXCL8 mediate osteosarcoma-lung interactions critical to metastasis. JCI Insight. 2018;3:e99791.","journal-title":"JCI Insight"},{"key":"803_CR89","doi-asserted-by":"publisher","first-page":"510","DOI":"10.18632\/oncotarget.27433","volume":"11","author":"M Charan","year":"2020","unstructured":"Charan M, Dravid P, Cam M, Setty B, Roberts RD, Houghton PJ, Cam H. Tumor secreted ANGPTL2 facilitates recruitment of neutrophils to the lung to promote lung pre-metastatic niche formation and targeting ANGPTL2 signaling affects metastatic disease. Oncotarget. 2020;11:510\u201322.","journal-title":"Oncotarget"},{"key":"803_CR90","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.3390\/ijms21155451","volume":"21","author":"A Mazumdar","year":"2020","unstructured":"Mazumdar A, Urdinez J, Boro A, Migliavacca J, Arlt MJE, Muff R, Fuchs B, Snedeker JG, Gvozdenovic A. Osteosarcoma-derived extracellular vesicles induce lung fibroblast reprogramming. Int J Mol Sci. 2020;21:5451.","journal-title":"Int J Mol Sci"},{"key":"803_CR91","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/j.celrep.2018.06.103","volume":"24","author":"W Zhang","year":"2018","unstructured":"Zhang W, Zhao J-M, Lin J, Hu C-Z, Zhang W-B, Yang W-L, Zhang J, Zhang J-W, Zhu J. Adaptive fibrogenic reprogramming of osteosarcoma stem cells promotes metastatic growth. Cell Rep. 2018;24:1266\u20131277.e5.","journal-title":"Cell Rep"},{"key":"803_CR92","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/ijc.34008","volume":"151","author":"Y Yui","year":"2022","unstructured":"Yui Y, Kumai J, Watanabe K, Wakamatsu T, Sasagawa S. Lung fibrosis is a novel therapeutic target to suppress lung metastasis of osteosarcoma. Int J Cancer. 2022;151:739\u201351.","journal-title":"Int J Cancer"},{"key":"803_CR93","doi-asserted-by":"publisher","first-page":"805978","DOI":"10.3389\/fonc.2022.805978","volume":"12","author":"K Wu","year":"2022","unstructured":"Wu K, Yu B, Li D, Tian Y, Liu Y, Jiang J. Recent advances in nanoplatforms for the treatment of osteosarcoma. Front Oncol. 2022;12:805978.","journal-title":"Front Oncol"},{"key":"803_CR94","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.bioactmat.2022.05.006","volume":"19","author":"G He","year":"2023","unstructured":"He G, Nie J-J, Liu X, et al. Zinc oxide nanoparticles inhibit osteosarcoma metastasis by downregulating \u03b2-catenin via HIF-1\u03b1\/BNIP3\/LC3B-mediated mitophagy pathway. Bioact Mater. 2023;19:690\u2013702.","journal-title":"Bioact Mater"},{"key":"803_CR95","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.2147\/IJN.S165699","volume":"13","author":"J Wang","year":"2018","unstructured":"Wang J, Gao S, Wang S, Xu Z, Wei L. Zinc oxide nanoparticles induce toxicity in CAL 27 oral cancer cell lines by activating PINK1\/Parkin-mediated mitophagy. Int J Nanomedicine. 2018;13:3441\u201350.","journal-title":"Int J Nanomedicine"},{"key":"803_CR96","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1021\/acsnano.0c09799","volume":"15","author":"Z Deng","year":"2021","unstructured":"Deng Z, Bi S, Jiang M, Zeng S. Endogenous H 2 S-activated orthogonal second near-infrared emissive nanoprobe for in situ ratiometric fluorescence imaging of metformin-induced liver injury. ACS Nano. 2021;15:3201\u201311.","journal-title":"ACS Nano"},{"key":"803_CR97","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1124\/mol.106.028837","volume":"71","author":"B Ory","year":"2007","unstructured":"Ory B, Blanchard F, Battaglia S, Gouin F, R\u00e9dini F, Heymann D. Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status. Mol Pharmacol. 2007;71:333\u201343.","journal-title":"Mol Pharmacol"},{"key":"803_CR98","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.bone.2005.02.020","volume":"37","author":"D Heymann","year":"2005","unstructured":"Heymann D, Ory B, Blanchard F, Heymann M-F, Coipeau P, Charrier C, Couillaud S, Thiery JP, Gouin F, Redini F. Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone. 2005;37:74\u201386.","journal-title":"Bone"},{"key":"803_CR99","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/S1470-2045(16)30096-1","volume":"17","author":"S Piperno-Neumann","year":"2016","unstructured":"Piperno-Neumann S, Le Deley M-C, R\u00e9dini F, et al. Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2016;17:1070\u201380.","journal-title":"Lancet Oncol"},{"key":"803_CR100","doi-asserted-by":"publisher","first-page":"78343","DOI":"10.18632\/oncotarget.13055","volume":"7","author":"C Dumars","year":"2016","unstructured":"Dumars C, Ngyuen J-M, Gaultier A, Lanel R, Corradini N, Gouin F, Heymann D, Heymann M-F. Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma. Oncotarget. 2016;7:78343\u201354.","journal-title":"Oncotarget"},{"key":"803_CR101","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1021\/acs.bioconjchem.9b00210","volume":"30","author":"E David","year":"2019","unstructured":"David E, Cagnol S, Goujon J-Y, et al. 12b80 \u2013 Hydroxybisphosphonate linked doxorubicin: bone targeted strategy for treatment of osteosarcoma. Bioconjug Chem. 2019;30:1665\u201376.","journal-title":"Bioconjug Chem"},{"key":"803_CR102","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00280-021-04371-6","volume":"89","author":"X-Z Wen","year":"2022","unstructured":"Wen X-Z, Pan Q-Z, Xu B-S, Xiao W, Weng D-S, Zhao J-J, Xu H-R, Huang Z, Niu X-H, Zhang X. Phase I study of pegylated liposomal doxorubicin and cisplatin in patients with advanced osteosarcoma. Cancer Chemother Pharmacol. 2022;89:209\u201315.","journal-title":"Cancer Chemother Pharmacol"},{"key":"803_CR103","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/j.nano.2018.05.015","volume":"14","author":"F Chen","year":"2018","unstructured":"Chen F, Zeng Y, Qi X, Chen Y, Ge Z, Jiang Z, Zhang X, Dong Y, Chen H, Yu Z. Targeted salinomycin delivery with EGFR and CD133 aptamers based dual-ligand lipid-polymer nanoparticles to both osteosarcoma cells and cancer stem cells. Nanomed Nanotechnol Biol Med. 2018;14:2115\u201327.","journal-title":"Nanomed Nanotechnol Biol Med"},{"key":"803_CR104","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1021\/acsabm.1c01087","volume":"5","author":"Y Liu","year":"2022","unstructured":"Liu Y, Wang Q, Liu X, Nakielski P, Pierini F, Li X, Yu J, Ding B. Highly adhesive, stretchable and breathable gelatin methacryloyl-based nanofibrous hydrogels for wound dressings. ACS Appl Bio Mater. 2022;5:1047\u201356.","journal-title":"ACS Appl Bio Mater"},{"key":"803_CR105","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1016\/j.bioactmat.2021.01.006","volume":"6","author":"J Liao","year":"2021","unstructured":"Liao J, Shi K, Jia Y, Wu Y, Qian Z. Gold nanorods and nanohydroxyapatite hybrid hydrogel for preventing bone tumor recurrence via postoperative photothermal therapy and bone regeneration promotion. Bioact Mater. 2021;6:2221\u201330.","journal-title":"Bioact Mater"},{"key":"803_CR106","doi-asserted-by":"publisher","first-page":"100379","DOI":"10.1016\/j.jbo.2021.100379","volume":"30","author":"J Munoz-Garcia","year":"2021","unstructured":"Munoz-Garcia J, Jubelin C, Loussouarn A, Goumard M, Griscom L, Renodon-Corni\u00e8re A, Heymann M-F, Heymann D. In vitro three-dimensional cell cultures for bone sarcomas. J Bone Oncol. 2021;30:100379.","journal-title":"J Bone Oncol"},{"key":"803_CR107","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s13578-022-00887-3","volume":"12","author":"C Jubelin","year":"2022","unstructured":"Jubelin C, Mu\u00f1oz-Garcia J, Griscom L, Cochonneau D, Ollivier E, Heymann M-F, Vallette FM, Oliver L, Heymann D. Three-dimensional in vitro culture models in oncology research. Cell Biosci. 2022;12:155.","journal-title":"Cell Biosci"},{"key":"803_CR108","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.drudis.2018.11.017","volume":"24","author":"HK Brown","year":"2019","unstructured":"Brown HK, Tellez-Gabriel M, Cartron P-F, Vallette FM, Heymann M-F, Heymann D. Characterization of circulating tumor cells as a reflection of the tumor heterogeneity: myth or reality? Drug Discov Today. 2019;24:763\u201372.","journal-title":"Drug Discov Today"},{"key":"803_CR109","doi-asserted-by":"publisher","first-page":"4580","DOI":"10.7150\/thno.34337","volume":"9","author":"M Tellez-Gabriel","year":"2019","unstructured":"Tellez-Gabriel M, Heymann M-F, Heymann D. Circulating tumor cells as a tool for assessing tumor heterogeneity. Theranostics. 2019;9:4580\u201394.","journal-title":"Theranostics"},{"key":"803_CR110","doi-asserted-by":"publisher","first-page":"100236","DOI":"10.1016\/j.jbo.2019.100236","volume":"16","author":"M Li","year":"2019","unstructured":"Li M, Lu Y, Long Z, Li M, Kong J, Chen G, Wang Z. Prognostic and clinicopathological significance of circulating tumor cells in osteosarcoma. J Bone Oncol. 2019;16:100236.","journal-title":"J Bone Oncol"},{"key":"803_CR111","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1093\/clinchem\/hvac019","volume":"68","author":"M Vismara","year":"2022","unstructured":"Vismara M, Reduzzi C, Silvestri M, et al. Single-cell phenotypic and molecular characterization of circulating tumor cells isolated from cryopreserved peripheral blood mononuclear cells of patients with lung cancer and sarcoma. Clin Chem. 2022;68:691\u2013701.","journal-title":"Clin Chem"},{"key":"803_CR112","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jbo.2018.07.002","volume":"12","author":"A Chalopin","year":"2018","unstructured":"Chalopin A, Tellez-Gabriel M, Brown HK, Vallette F, Heymann M-F, Gouin F, Heymann D. Isolation of circulating tumor cells in a preclinical model of osteosarcoma: effect of chemotherapy. J Bone Oncol. 2018;12:83\u201390.","journal-title":"J Bone Oncol"},{"key":"803_CR113","first-page":"366","volume":"35","author":"A Nawan","year":"2022","unstructured":"Nawan A, Qiang ZS, Qiang HX, Geng W. Detection and quantification of circulating tumor cells in salvaged blood in surgical osteosarcoma patients: a pilot study from a tertiary medical center. Biomed Environ Sci. 2022;35:366\u20139.","journal-title":"Biomed Environ Sci"},{"key":"803_CR114","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1158\/0008-5472.CAN-13-1739","volume":"74","author":"A Satelli","year":"2014","unstructured":"Satelli A, Mitra A, Cutrera JJ, et al. Universal marker and detection tool for human sarcoma circulating tumor cells. Cancer Res. 2014;74:1645\u201350.","journal-title":"Cancer Res"},{"key":"803_CR115","doi-asserted-by":"publisher","first-page":"100357","DOI":"10.1016\/j.jbo.2021.100357","volume":"28","author":"HO Fasanya","year":"2021","unstructured":"Fasanya HO, Dopico PJ, Yeager Z, Fan ZH, Siemann DW. Using a combination of gangliosides and cell surface vimentin as surface biomarkers for isolating osteosarcoma cells in microfluidic devices. J Bone Oncol. 2021;28:100357.","journal-title":"J Bone Oncol"},{"key":"803_CR116","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/s41416-022-01776-9","volume":"127","author":"M Garc\u00eda-Pardo","year":"2022","unstructured":"Garc\u00eda-Pardo M, Makarem M, Li JJN, Kelly D, Leighl NB. Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges. Br J Cancer. 2022;127:592\u2013602.","journal-title":"Br J Cancer"},{"key":"803_CR117","doi-asserted-by":"publisher","first-page":"12695","DOI":"10.18632\/oncotarget.24268","volume":"9","author":"DM Barris","year":"2018","unstructured":"Barris DM, Weiner SB, Dubin RA, et al. Detection of circulating tumor DNA in patients with osteosarcoma. Oncotarget. 2018;9:12695\u2013704.","journal-title":"Oncotarget"},{"key":"803_CR118","first-page":"1","volume":"168","author":"I Lyskj\u00e6r","year":"1990","unstructured":"Lyskj\u00e6r I, Kara N, De Noon S, et al. (2022) Osteosarcoma: novel prognostic biomarkers using circulating and cell-free tumour DNA. Eur J Cancer Oxf Engl. 1990;168:1\u201311.","journal-title":"Eur J Cancer Oxf Engl"},{"key":"803_CR119","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1038\/s41467-021-23445-w","volume":"12","author":"P Peneder","year":"2021","unstructured":"Peneder P, St\u00fctz AM, Surdez D, et al. Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden. Nat Commun. 2021;12:3230. Interesting study providing a comprehensive analysis of circulating tumor DNA and their clinical association for childhood cancers.","journal-title":"Nat Commun"},{"key":"803_CR120","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41416-018-0212-9","volume":"119","author":"DS Shulman","year":"2018","unstructured":"Shulman DS, Klega K, Imamovic-Tuco A, et al. Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children\u2019s Oncology Group. Br J Cancer. 2018;119:615\u201321.","journal-title":"Br J Cancer"}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-023-00803-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11914-023-00803-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-023-00803-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T04:22:52Z","timestamp":1690863772000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11914-023-00803-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,17]]},"references-count":120,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["803"],"URL":"https:\/\/doi.org\/10.1007\/s11914-023-00803-9","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,17]]},"assertion":[{"value":"5 June 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}